腹腔镜Roux-en-Y胃旁路术与腹腔镜胃袖状切除术治疗肥胖病的对比研究

目的比较腹腔镜Roux-en-Y胃旁路术(laparoscopic Roux-en-Y gastric bypass,LRYGB)与腹腔镜胃袖状切除术(laparoscopic sleeve gastrectomy,LSG)治疗肥胖病的疗效。方法 2012年1月~2014年1月符合入组条件的肥胖病49例,术前BMI 38.85±6.40(32.01~58.64),其中42例(86%)合并2型糖尿病,37例(76%)合并高甘油三酯血症(hypertriglyceridemia,HTG)。根据患者选择的手术方式分为LRYGB组(n=26)和LSG组(n=23),将临床资料进行对比研究。结果 2组均成功实施手术。LRYGB组手术时间明显长于LSG组[(108.8±16.1)min vs.(90.9±24.8)min,t=3.031,P=0.004]。术后随访12~28个月,平均16个月。49例术后12个月BMI 29.75±3.46,与术前相比明显下降(t=14.135,P=0.000);术后多余体重减除率(EWL%)80.06%±14.28%(51.00%~120.00%)。42例合并2型糖尿病者术后空腹血糖和糖化血红蛋白较术前明显下降[(9.23±3.40)mmol/L vs.(8.00±1.94)mmol/L,t=3.168,P=0.003;6.22%±1.63%vs.5.43%±0.93%,t=7.212,P=0.000];37例合并HTG患者术后甘油三酯水平较术前亦下降[(2.49±0.77)mmol/L vs.(1.64±0.68)mmol/L,t=5.202,P=0.000]。2组体重减轻、降糖、降脂效果无明显差异(P均0.05)。结论LRYGB与LSG治疗肥胖病是安全有效的,对合并2型糖尿病及高甘油三酯血症也有较好的疗效。LSG操作相对简单,符合胃肠道生理,值得优先选择。     

重度肥胖患者腹腔镜胃旁路术后味觉的改变

目的:探讨腹腔镜Roux-en-Y胃旁路术(laparoscopic Roux-en-Y gastric bypass,LRYGB)对重度肥胖患者味觉的影响。方法:前瞻性地选择13例BMI平均为(38.6±3)kg/m2的重度肥胖患者作为研究对象,利用味觉问卷评估患者LRYGB术前及术后3个月的味觉变化情况。结果:术后12人(92.3%)饮食后口味发生了变化,较术前2人(15.4%)差异有统计学意义(P=0.006),患者术后食用甜食、肉类、脂类较术前明显降低,分别为(6.31±1.25)vs.(7.77±1.09)(P=0.000),(6.77±1.01)vs.(8.54±1.13)(P=0.000),(5.85±1.28)vs.(6.77±1.3)(P=0.004),手术前后在"甜食口感下降、咸食口感下降及总体口感下降"3方面均存在明显差异,分别为:0 vs.61.5%(P=0.008),0 vs.46.2%(P=0.031),15.4%vs.84.6%(P=0.039),肥胖患者术后对"味觉在享受食物的重要性"的认可度,由术前的(6.92±1.38)上升至(8.46±0.78),差异有统计学意义(P=0.000)。结论:术后患者对食物、饮料的口味发生了变化,并且出现部分味觉受损,尤其对甜食、咸食、总体口感的下降影响了肥胖患者LRYGB术后食物的摄入量。     

腹腔镜下Roux-en-Y胃旁路术治疗肥胖型2型糖尿病疗效观察

探讨腹腔镜下Roux-en-Y胃旁路术(LRYGB)治疗肥胖型2型糖尿病(T2DM)的疗效。以2010年8月—2014年10月在我院消化中心接受LRYGB的30例肥胖型T2DM患者为研究对象,于术前及术后1、3、6、14个月取静脉血,检测肥胖相关指标:体重、体重指数(BMI)、腰围、多余体重减少率(EWL);T2DM代谢相关指标:空腹及餐后2 h血糖、糖化血红蛋白(HbA1c)、C肽水平;计算T2DM缓解率和LRYGB术后相关并发症发生率。30例患者均顺利完成LRYGB,平均手术时间(96±28)min,出血量(42±6)m L,无严重并发症发生。术后3、6、14个月时,患者体重、腹围、BMI明显下降,而空腹及餐后2 h血糖、HbA1c从术后1个月开始即明显下降,与术前比较差异均有统计学意义(P0.05)。术后3、6、14个月时BMI、空腹血糖均较术后1个月显著下降(P0.05);而血清C肽水平在各时点差异无统计学意义(P0.05)。在减重方面,术后3、6、14个月EWL分别为(76.1±34.0)%、(79.6±45.0)%和(52.7±32.0)%;在T2DM缓解率方面,完全缓解率达83%。LRYGB治疗肥胖型T2DM可以在短期内减重并改善糖代谢。     

减重代谢手术治疗肥胖合并重度阻塞性睡眠呼吸暂停短期疗效分析

目的分析和比较腹腔镜胃袖状切除术(LSG)和腹腔镜胃旁路手术(LRYGB)对肥胖合并重度阻塞性睡眠呼吸暂停(OSA)病人的短期治疗效果。方法回顾性分析上海交通大学医学院附属第九人民医院普外科2016年1月至2017年1月收治的52例肥胖合并重度OSA并接受减重代谢手术病人的临床资料,按手术方式分为LSG组(32例)和LRYGB(20例),评估手术风险以及手术对体重、OSA病情的影响。结果术后短期随访6个月,两组病人均无严重并发症发生。LSG组与LRYGB组两组手术时间、术中失血量和住院时间差异有统计学意义(P0.01)术后两组肥胖和OSA病情均有缓解,其中LSG组术后6个月呼吸暂停低通气指数(AHI)与术前AHI差异有统计学意义[(25.9±7.8)次/h vs.(69.7±11.4)次/h,P0.05];LRYGB组术后AHI与术前AHI相比差异有统计学意义[(24.9±6.7)次/h vs.(66.8±10.5)次/h,P0.05],而两组间差异无统计学意义(P0.05)。术前AHI可能是影响减重手术治疗肥胖合并OSA疗效的独立影响因素。结论 LSG和LRYGB均可以有效治疗肥胖合并重度OSA的病情,短期疗效明显,长期效果仍待观察研究。     

机器人手术治疗子宫内膜癌合并肥胖

目的探讨达芬奇机器人手术治疗子宫内膜癌合并肥胖患者(BMI≥28)的可行性和安全性。方法选取2013年1月~2015年12月73例子宫内膜癌,其中27例BMI≥28行机器人手术(机器人组),46例BMI28行腹腔镜手术(腹腔镜组),比较2组术中、术后情况。结果 2组手术时间[(239.4±40.7)min vs.(233.0±52.5)min,t=0.544,P=0.588]、术中出血量[(136.1±85.0)ml vs.(121.7±76.3)ml,t=0.746,P=0.458]、盆腔淋巴结切除数[(23.1±9.8)枚vs.(20.9±12.0)枚,t=0.807,P=0.422]、腹主动脉旁淋巴结切除数[(2.1±1.3)枚vs.(2.3±1.7)枚,t=-0.527,P=0.600]、总淋巴结切除数[(24.4±11.1)枚vs.(22.4±13.5)枚,t=0.651,P=0.517]和术中输血率[18.5%(5/27)vs.19.6%(9/46),χ~2=0.012,P=0.913]均无统计学差异。2组术后早期[18.5%(5/27)vs.19.6%(9/46),χ~2=0.012,P=0.913]、晚期并发症发生率[3.7%(1/27)vs.4.3%(2/46),χ~2=0.000,P=1.000]和住院时间[(19.8±6.3)d vs.(18.7±6.2)d,t=0.727,P=0.469]无统计学差异。结论达芬奇机器人手术系统行子宫内膜癌分期手术治疗子宫内膜癌合并肥胖安全、可行。     

腹腔镜Roux-en-Y胃旁路术治疗2型糖尿病及其并发症的临床疗效观察

目的探讨腹腔镜Roux-en-Y胃旁路术(Laparoscopic Roux—en-Y gastric bypass,LRYGB)对2型糖尿病(type 2 diabetes mellitus,T2DM)及其并发症的长期临床疗效。方法回顾性分析我院收治的48例T2DM患者的临床资料。术后随访4年,分析术前及术后体重指数(BMI)、腰臀比(WHR)、糖脂代谢指标的变化。同时观察T2DM相关并发症的改善情况。结果48例手术均在腹腔镜下顺利完成,无一例中转开腹,随访期间,无死亡病例及严重手术并发症发生。48例T2DM患者的BMI及WHR在术后3个月、6个月、1年、2年、3年、4年均较术前显著下降,差异有统计学意义(P0.05)。同时,糖代谢相关指标空腹血糖(FPG)、标准馒头餐后2h血糖(2h PG)、空腹C肽(FC-P)、糖化血红蛋白(HbA1c)于术后各时间点均较术前明显下降(P0.05)。与术前比较,脂代谢相关指标TC、TG、HDL、LDL于术后各时间点均较术前明显改善(P0.05)。48例接受LRYGB的T2DM患者有效率达100%。结论腹腔镜Roux-en-Y胃旁路术是治疗2型糖尿病的一种安全有效的手术方式,完善的术前评估、围手术期规范化的管理及长期随访是保证手术疗效的关键。     

腹腔镜胃旁路术治疗非肥胖2型糖尿病的疗效与安全性分析

目的探讨腹腔镜Roux-en-Y胃旁路术（LRYGB）治疗非肥胖2型糖尿病（T2DM）的疗效及安全性。 方法收集2016年1月至2017年6月在贵州省人民医院普外科行LRYGB的28例T2DM患者的临床资料。根据术前体质量指数（BMI）将患者分为非肥胖组（BMI≤27.5 kg/m²）11例和肥胖组（BMI>27.5 kg/m²）17例。分析两组患者术前和术后3、6、9、12个月空腹血糖（FPG）、糖化血红蛋白（HbA1c）、空腹C肽（FCp）、空腹胰岛素（FIns）的变化及并发症情况。 结果两组患者均顺利完成手术,手术时间及出血量比较差异无统计学意义（t=0.642、0.871,P=0.526、0.392）,术后均无严重并发症发生,术后BMI、FPG、HbA1c、FCp、FIns随着时间的推移均呈持续下降的趋势,且明显低于术前水平（P<0.05）。非肥胖组患者BMI在各时间点均低于肥胖组患者（P<0.05）,术后12个月时非肥胖组的FCp水平显著低于肥胖组（t=0.711,P<0.05）。非肥胖组和肥胖组术后1年T2DM完全缓解率分别为72.7%（8/11）和82.4%（14/17）,差异无统计学意义（χ²=0.368,P=0.544）。 结论LRYGB能明显降低非肥胖型T2DM患者的体质量,并改善糖代谢情况,且手术安全。     

全胸腔镜肺叶切除对腹型肥胖低肺功能肺癌患者术后心肺功能的影响

目的探讨全胸腔镜肺叶切除对腹型肥胖低肺功能肺癌患者术后心肺功能的影响。方法 2013年7月~2014年6月对23例腹型肥胖伴低肺功能肺癌行全胸腔镜肺叶切除术,观察术后1周内心肺并发症,术前2 d,术后第3、7天,1.5、3、6个月行肺功能检查及登楼试验,评价心肺功能。结果术后心肺并发症发生率39.1%(9/23)。术后第3天较术前FVC[(1.83±0.45)L vs.(2.70±0.68)L,q=7.936,P0.05]、FEV1.0[(1.05±0.29)L vs.(1.75±0.25)L,q=9.745,P0.05]、FEV1.0/FVC[(53.3±7.6)%vs.(70.2±6.0)%,q=9.902,P0.05]、MVV[(55.3±14.9)L/min vs.(86.8±16.5)L/min,q=9.279,P0.05]、FRC[(1.50±0.27)L vs.(2.25±0.35)L,q=8.920,P0.05]明显下降,术后第7天较术前FVC[(2.07±0.53)L vs.(2.70±0.68)L,q=5.747,P0.05]、FEV1.0[(1.35±0.31)L vs.(1.75±0.25)L,q=5.568,P0.05]、FEV1.0/FVC[(57.6±7.4)%vs.(70.2±6.0)%,q=7.382,P0.05]、MVV[(66.3±15.8)L/min vs.(86.8±16.5)L/min,q=6.038,P0.05]、FRC[(1.68±0.35)L vs.(2.25±0.35)L,q=6.779,P0.05]下降明显;术后第7天与第3天比较,FEV1.0[(1.35±0.31)L vs.(1.05±0.29)L,q=4.176,P0.05]、MVV[(66.3±15.8)L/min vs.(55.3±14.9)L/min,q=3.240,P0.05]有统计学差异,在短期内恢复;术后1.5月较术后第3、7天FVC、FEV1.0/FVC、MVV明显好转(P0.05),与术后3、6个月无统计学差异(P0.05),肺功能趋于稳定;FVC、FEV1.0、FEV1.0/FVC、MVV术后6个月与术前比较无统计学差异(P0.05),表明肺功能已恢复到术前水平。登楼试验显示术后第7天仅2例(8.7%)能坚持到5楼,且HR明显升高、登楼时间延长及Sp O2下降均≥5%;术后1.5月登楼成功例数与术前无差异(P0.05),术后3个月仅登楼时间较术前有明显差异(P0.05)。结论腹型肥胖低肺功能肺癌患者行全胸腔镜肺叶切除术后1周对心肺功能影响明显,注意加强围手术期管理,1.5月后心肺功能逐渐代偿,恢复满意。     

肥胖对腹腔镜右半结肠癌完整结肠系膜切除疗效的影响

目的探讨肥胖对腹腔镜右半结肠癌完整结肠系膜切除(complete mesocolic excision,CME)手术和预后的影响。方法回顾性分析我院2012年2月~2016年1月96例腹腔镜右半结肠癌CME手术的临床资料,其中肥胖组27例(BMI≥28),非肥胖组69例(BMI28),比较2组手术指标和术后生存情况。结果与非肥胖组比较,肥胖组手术时间长[(151.5±15.9)min vs.(142.6±19.3)min,t=2.123,P=0.036],术中出血多[(90.7±55.5)ml vs.(66.7±33.9)ml,t=2.583,P=0.011],术后排气晚[(3.1±1.0)d vs.(2.5±1.1)d,t=2.238,P=0.028],术后住院时间长[(8.8±3.3)d vs.(7.6±2.3)d,t=2.048,P=0.043],术后并发症发生率高[37.0%(10/27)vs.15.9%(11/69),χ~2=5.053,P=0.025],2组中转开腹率无显著性差异[7.4%(2/27)vs.1.4%(1/69),Fisher检验,P=0.190]。2组淋巴结清扫数目[(21.0±4.0)枚vs.(21.6±4.1)枚,t=-0.732,P=0.466],淋巴结转移率[44.4%(12/27)vs.49.3%(34/69),χ~2=0.181,P=0.670],阳性淋巴结数[(4.3±2.2)枚vs.(4.4±2.3)枚,t=-0.063,P=0.950],肿瘤TNM分期(χ~2=0.594,P=0.743)均无显著性差异。2组生存曲线无显著性差异(log-rankχ~2=0.398,P=0.528)。结论肥胖增加了腹腔镜右半结肠癌CME手术操作的难度,术后恢复慢,但对患者术后生存无明显影响。     

达芬奇机器人与腹腔镜胃癌根治术围手术期疗效与营养状况的对比分析

目的:探讨达芬奇机器人胃癌根治术治疗进展期胃癌的疗效、应激反应及营养状况,以明确达芬奇机器人手术系统相较腹腔镜手术在术中损伤控制、围手术期营养方面的优势。方法:回顾分析2017年6月至2019年6月施行全胃切除术及Roux-en-Y吻合的279例患者的临床资料,其中162例行达芬奇机器人全胃切除术(RATG)及Roux-en-Y吻合(RATG组),117例行腹腔镜全胃切除术(LATG)加Roux-en-Y吻合(LATG组),比较两组患者基本资料、术后应激反应指标及营养状况。术后并发症根据并发症Clavien-Dindo分级系统进行分析。结果:RATG组手术时间长于LATG组[(240.91±22.38)min vs.(230.34±37.39)min,P<0.05],清扫淋巴结数量多于LATG组[(46.05±11.33)vs.(39.52±9.33),P<0.05],术后通气时间早于LATG组[(2.67±0.96)d vs.(2.94±1.09)d,P<0.05],术后住院时间短于LATG组[(9.89±3.70)d vs.(11.66±4.65)d,P<0.05],术后Ⅲ级并发症少于LATG组。RATG组IL-6于术后第1天[(20.65±4.36)pg/dL vs.(26.26±6.99)pg/dL,P<0.05]、第3天[(10.14±1.30)pg/dL vs.(11.34±1.78)pg/dL,P<0.05]低于LATG组,术后第3天C反应蛋白[(15.39±1.45)mg/dL vs.(16.29±1.33)mg/dL,P<0.05]低于LATG组,术后第1天白细胞[(11.41±1.88)×10⁹/L vs.(12.48±2.10)×10⁹/L,P<0.05]低于LATG组。在术后短期营养方面,RATG组血清白蛋白第1天[(3.22±0.72)g/dL vs.(2.96±0.53)g/dL,P<0.05]、第3天[(3.14±0.76)g/dL vs.(2.90±0.78)g/dL P<0.05]高于LATG组。第3天营养预后指数[(40.57±3.84)vs.(39.66±2.39),P<0.05]高于LATG组。结论:达芬奇机器人手术系统可有效控制术中损伤,进而改善进展期胃癌患者围手术期营养状况。     

腹腔镜Roux-en-Y胃旁路手术治疗肥胖症和2型糖尿病

目的 探讨腹腔镜Roux-en-Y胃旁路手术（LRYGB）治疗肥胖症和（或）2型糖尿病的可行性及疗效.方法 对21例单纯性肥胖症及9例2型糖尿病患者施行LRYGB,观察肥胖症患者体质量、BMI、超重体质量减少率（EWL%）改善情况;观察糖尿病患者术后的空腹血糖和口服葡萄糖耐量试验（OGTT）变化情况;观察全组患者手术时间、术中出血量、术后恢复、术后并发症情况.结果 本组30例皆成功完成手术,无中转开放手术者,手术时间110～270（平均168）min.术中出血量10～75（平均24.0）ml.本组21例单纯性肥胖症患者术前体质量及BMI分别为（97.2±15.0）kg和35.3±3.5;术后随访2个月至5年,术后1个月体质量及BMI即显著下降[（85.1±10.1）kg和31.2±2.2,均P〈0.01],至术后2～3年降至最低水平[（66.8±9.2）kg和24.3±1.1],之后维持在此水平;EWL%则相应增高（均P〈0.05）.9例2型糖尿病患者术前空腹血糖及OGTT 2 h血糖分别为（12.6±2.6）mmol/L和（17.8±4.1）mmol/L;术后随访3～8个月,空腹血糖及OGTT2 h血糖均显著下降[（5.9±1.4）mmol/L和（7.8±1.4）mmol/L,均P〈0.05];其中合并肥胖症的4例患者BMI明显降低（P〈0.05）,而5例未合并肥胖症者BMI无明显变化（P〉0.05）.本组30例患者中5例（16.7%）术后出现并发症,其中1例因急性暴发性胰腺炎死亡外,1例因肠系膜裂孔疝致肠梗阻行再次手术治愈,余3例均经保守治疗治愈.结论 LRYGB治疗肥胖症和（或）2型糖尿病手术安全可行,术后近期减重和（或）降糖效果显著.     

2型糖尿病男性患者骨密度与性激素水平关系的研究

目的通过比较不同骨密度(bone mineral density,BMD)状态的2型糖尿病(type 2 diabetes mellitus,T2DM)男性患者性激素水平的差异,进一步探讨性激素与T2DM男性患者BMD的关系。方法收集2013年6月至2015年1月我院住院的男性T2DM患者84例,年龄在45~60岁。采用美国Norland双能X线骨密度检测仪对所有患者进行第1~4腰椎(L1~L4)、股骨颈(FN)及全髋(TH)部位BMD检测,根据BMD分为骨量正常组和骨量异常组(包括骨量减少和骨质疏松)。测定身高、体重、SBP、DBP等一般情况指标,并计算体重指数(body mass index,BMI);FBG、PBG、Hb Alc等糖代谢指标;TC、TG、LDL等脂代谢指标,T、E2、LH及FSH。结果 1与骨量正常组相比,骨量异常组病程更长,BMI更低,E2及T水平也显著降低。2相关分析显示,T与L1~L4、FN及TH三个部位BMD均呈正相关;E2仅与TH的BMD呈正相关;TC、LDL分别与FN的BMD呈负相关。3多元线性回归分析显示,在T2DM男性患者中,T及TC是影响FN的BMD的主要因素,而E2、LH、FSH未进入回归模型。结论 E2、T等性激素水平,TC、LDL等脂代谢指标与男性T2DM患者BMD相关,其中性激素中T是影响T2DM男性患者BMD的独立危险因素。     

腹腔镜D2根治术治疗进展期胃癌的近期疗效分析

目的:探讨腹腔镜与开腹胃癌根治术治疗进展期胃癌的近期疗效。方法:回顾分析手术治疗的89例进展期胃癌患者的临床资料,其中46例行腹腔镜下胃癌根治术(腹腔镜组),43例行传统开腹胃癌根治术(开腹组),対比分析两种术式的优缺点。结果:腹腔镜组与开腹组手术时间[(188.37±9.50)min vs.(167.33±6.76)min]、术中失血量[(65.54±6.34)ml vs.(111.05±14.74)ml]、术后排气时间[(59.74±14.86)h vs.(82.88±15.45)h]、术后进食时间[(61.93±14.90)h vs.(84.91±15.42)h]、术后镇痛药应用次数[(2.87±1.15)vs.(4.12±1.07)]及术后住院时间[(12.28±1.63)d vs.(15.28±0.77)d]等方面差异有统计学意义(P0.05);术后并发症发生率[2(4.35%)vs.5(11.63%)]、清扫淋巴结数量[(25.87±1.22)枚vS.(25.91±1.11)枚]差异无统计学意义(P0.05)。结论:腹腔镜下D2根治术治疗进展期胃癌是安全、可行的,相较传统开腹手术存在多方面优势。     

��ǻ��θ��·����ҩ�����Ʒ��ֺϲ�2��������Ч�ȽϷ���

??Outcomes of laparoscopic Roux-en-Y gastric bypass and medical therapy in obese patients with type 2 diabetes ZHANG Chen*, ZHAO Hong-zhi, QIAN Dong, et al. *Tianjin Nankai Hospital, Tianjin 300100, China
Corresponding author: ZHAO Hong-zhi, E-mail: tjzhhzh@126.com
Abstract Objective To observe and evaluate therapeutic results of laparoscopic Roux-en-Y gastric bypass (LRYGB) and medical therapy for the patients of obesity with type 2 diabetes mellitus (T2DM). Methods A randomized controlled trial was conducted among the 180 obese patients with T2DM who were selected from Tianjin Nankai Hospital (107 cases) and Tianjin Medical University Metabolic Diseases Hospital (73 cases) from 2010 to 2013. The 180 cases were randomly divided into LRYGB group and medical therapy group (90 cases per group). The 3 years follow-up outcomes of BMI, %EWL and data about diabetes were analyzed. Results There were 87 (96.7%) and 88 (97.8%) cases who were observed and followed up for 3 years in each group. The operations were successful in LRYGB group. After 3-year follow up, in the LRYGB group, the BMI changed from 39.5 ±3.7 to 29.3 ±6.2; %EWL was (66.0 ±7.3) %; the glycosylated hemoglobin (HbA1c) changed from (8.6 ±3.0) % to (6.8±2.0) %; the fast blood glucose (FBG) changed from (9.6 ±2.8) mmol/L to (7.2 ±3.5) mmol/L. In medical group, BMI changed from 38.8 ±6.0 to 38.2 ±6.7; %EWL was (3.8 ±6.2) %; the HbA1c changed from (9.0 ±3.6??% to (8.5 ±3.8??%; the FBG changed from (9.7 ±3.3??mmol/L to (9.3 ±3.1?? mmol/L. The differences of outcomes regarding obesity and diabetes were significant statistically??P<0.05??. Conclusion The short term effect of LRYGB in obesity and T2DM is reliable and superior to the medical therapy. Diabetes remission rate of LRYGB is 64.4%, without any severe complications. LRYGB is an effective method which can be used to treat the Chinese obese patients with T2DM.     

Equivalent Weight Loss with Marked Metabolic Benefit Observed in a Matched Cohort with and Without Type 2 Diabetes 12?Months Following Gastric Bypass Surgery

Background

Bariatric surgery results in dramatic weight loss and improves metabolic syndrome and type 2 diabetes (T2DM). However, previous studies have noted that morbidly obese patients with T2DM experience less weight loss benefits than non-diabetic patients following bariatric surgery. We sought to determine longitudinal effects of laparoscopic Roux-en-Y gastric bypass (LRYGB) on percent excess body mass index (BMI) loss (%EBMIL) and clinical metabolic syndrome parameters in patients with T2DM compared with appropriately matched cohort without T2DM.

Methods

Retrospective cohort analysis of T2DM patients (n?=?126) to non-T2DM patients (n?=?126) matched on age (M?=?48.1?±?9.5), sex (81?% female), race (81?% Caucasian), and pre-surgical BMI (M?=?49.3?±?9.5). Lipids, glucose, hemoglobin A1c, blood pressure, co-morbidities of obesity, medications for co-morbidities, and T2DM medications were collected at baseline, 6?months and 12?months post-surgery. %EBMIL was collected at 1, 3, 6, 9, and 12?months post-surgery. One-way analyses of variance with effect sizes estimates were conducted to compare the two groups.

Results

As expected, T2DM subjects had significantly greater pre-surgical HbA1c, blood glucose, blood pressure, and lipid parameters at baseline vs. non-T2DM (all p values of<0.05). At 1, 3, 6, 9, and 12?months after LRYRB, both groups had similar reduction in %EBMIL (p?>?0.10). At 6?months, there was a significant reduction in HbA1c, blood glucose, and lipid in the T2DM cohort compared with pre-surgical levels (p?<?0.0001). At 12?months, these values were not different to that of the non-T2DM subjects (p?>?0.10).

Conclusions

When matched on appropriate factors associated with weight loss outcomes, severely obese patients with T2DM have similar post-LRYGB weight loss outcomes in the first 12?months following surgery compared with non-T2DM patients. Furthermore, T2DM surgical patients achieved significant improvement in metabolic syndrome components.     

Clinical Efficacy of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Gastric Bypass in Obese Type 2 Diabetic Patients: a Retrospective Comparison

Background

Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are performed in patients with obesity and type 2 diabetes mellitus (T2DM). The aim of this study is to evaluate retrospectively the clinical efficacy of RYGB and SG in two groups of obese T2DM patients.

Methods

From the hospital database, we extracted the clinical records of 31 obese T2DM patients, of whom 15 (7 F/8 M) had undergone laparoscopic SG (LSG) and 16 (7 F/9 M) laparoscopic RYGB (LRYGB) in the period 2005?C2008. The groups were comparable for age (range 33?C59?years) and BMI (range 38?C57?kg/m²). LRYGB alimentary limb was 150?cm, and biliopancreatic limb was 150?cm from the Treitz ligament. LSG vertical transection was calibrated on a 40-Fr orogastric bougie. Data were analysed at 6, 12 and 18?C24?months with reference to weight loss and remission of comorbidities.

Results

The reduction in body weight was comparable in the two groups. At 18?C24?months the percent BMI reduction was 29?±?8 and 33?±?11?% in LSG and LRYGB, respectively. Percent excess weight loss was 53?±?16 and 52?±?19?% in LSG and LRYGB, respectively. Thirteen patients in LSG and 14 patients in LRYGB discontinued their hypoglycaemic medications. Five (55?%) patients in LSG and eight (89?%) in LRYGB discontinued antihypertensive drugs. Three out of five patients in LSG and one out of two patients in LRYGB withdrew lipid-lowering agents.

Conclusions

LSG and LRYGB are equally effective in terms of weight loss and remission of obesity-related comorbidities. Controlled long-term comparisons are needed to establish the optimal procedure in relation to patients?? characteristics.     

Effect of Laparoscopic Roux-en-Y Gastroenterostomy with BMI?<?35?kg/m2 in Type 2 Diabetes Mellitus

Background

Roux-en-Y gastric bypass (RGB) has been endorsed by the ??First World Congress on International Therapies for Type 2 diabetes?? as a possible therapeutic option in patients with type 2 diabetes with a body mass index (BMI) of less than 35?kg/m². In the present study, we assessed the improvement in clinical indicators associated with laparoscopic Roux-en-Y gastric bypass (LRYGB) in patients with non-obese type 2 diabetes mellitus (T2DM).

Methods

LRYGB was performed in 30 T2DM patients with a BMI <35?kg/m². The patients were followed up for 1?year. Pre- and postoperative changes in BMI, waist circumference, and biochemical indicators including fasting plasma glucose and glycosylated hemoglobin were recorded.

Results

Significant reduction in glycosylated hemoglobin from 8.02?±?1.77 to 5.59?±?1.02?% (p?Conclusions LRYGB is beneficial for non-obese T2DM patients in China.     

骨小梁评分在2型糖尿病患者中评价骨质量的应用

目的探讨骨小梁评分(trabecular bone score,TBS)在评价2型糖尿病患者骨质量中的应用。方法回顾性分析128例2型糖尿病患者和64例非糖尿病患者的腰椎骨密度(bone mineral density,BMD)图像,通过骨小梁评分软件(TBS i Nsight software)计算得出骨小梁评分,分析两组患者的骨密度、骨小梁评分差异,并分析骨小梁评分和骨密度、年龄、体重的关系。结果和非糖尿病组相比,2型糖尿病患者组腰椎BMD升高(0.9103±0.1742 vs 0.8382±0.1422,P=0.005),TBS降低(1.2787±0.122 vs 1.3166±0.1016,P=0.033),在排除年龄、体重、骨密度的干扰后差异依然有统计学意义(P=0.008);相关性分析方面发现TBS和年龄呈负相关(r=-0.395,P0.001),和体质量指数呈负相关(r=-0.270,P0.001); TBS和腰椎BMD呈正相关,非糖尿病患者比糖尿病患者的相关性更强(r=0.563,P0.001 vs r=0.766,P0.001)。结论在2型糖尿病患者中骨小梁评分降低,这和2型糖尿病患者骨折风险增高的事实相符合,骨小梁评分可能成为评估2型糖尿病患者骨质量的指标。     

Glycemic Control after Sleeve Gastrectomy and Roux-En-Y Gastric Bypass in Obese Subjects with Type 2 Diabetes Mellitus

Background

Roux-en-Y gastric bypass (LRYGB) has weight-independent effects on glycemia in obese type 2 diabetic patients, whereas sleeve gastrectomy (LSG) is less well characterized. This study aims to compare early weight-independent and later weight-dependent glycemic effects of LRYGB and LSG.

Methods

Eighteen LRYGB and 15 LSG patients were included in the study. Glucose, insulin, GLP-1, and GIP levels were monitored during a modified 30 g oral glucose tolerance test before surgery and 2 days, 3 weeks, and 12 months after surgery. Patients self-monitored glucose levels 2 weeks before and after surgery.

Results

Postoperative fasting blood glucose decreased similarly in both groups (LRYGB vs. SG; baseline—8.1?±?0.6 vs. 8.2?±?0.4 mmol/l, 2 days—7.8?±?0.5 vs. 7.4?±?0.3 mmol/l, 3 weeks—6.6?±?0.4 vs. 6.6?±?0.3 mmol/l, respectively, P <?0.01 vs. baseline for both groups; 12 months—6.6?±?0.4 vs. 5.9?±?0.4, respectively, P <?0.05 for LRYGB and P <?0.001 for LSG vs. baseline, P =?ns between the groups at all times). LSG, but not LRYGB, showed increased peak insulin levels 2 days postoperatively (mean?±?SEM; LSG +?58?±?14%, P <?0.01; LRYGB ??8?±?17%, P =?ns). GLP-1 levels increased similarly at 2 days, but were higher in LRYGB at 3 weeks (AUC; 7525?±?1258 vs. 4779?±?712 pmol?×?min, respectively, P <?0.05). GIP levels did not differ. Body mass index (BMI) decreased more after LRYGB than LSG (??10.1?±?0.9 vs. ??7.9?±?0.5 kg/m², respectively, P <?0.05).

Conclusion

LRYGB and LSG show very similar effects on glycemic control, despite lower GLP-1 levels and inferior BMI decrease after LSG.

     

2型糖尿病合并骨质疏松患者外周血中VDR mRNA表达与25(OH)D、甘油三酯的关系研究

目的探讨2型糖尿病(type 2 diabetes mellitus,T2DM)合并骨质疏松(osteoporosis,OP)患者血浆中维生素D受体(vitamin D receptor,VDR)mRNA表达水平与25羟维生素D[25 hydroxyvitamin D,25(OH)D]、甘油三酯(triglyceride,TG)的关系。方法选取2016年6月至2017年5月就诊于遵义医科大学附属医院内分泌科门诊及住院治疗的初诊2型糖尿病患者100例,据骨密度(bone mineral density,BMD)测定结果分为:单纯T2DM组48例,T2DM合并骨质疏松组(T2DM+OP组)52例;选取遵义医科大学体检中心年龄及性别相匹配的健康对照者(NC组)90例。采用电化学发光法检测血清25(OH)D水平,全自动生化分析仪检测TG,采用实时荧光定量聚合酶链反应(Real Time-PCR)检测外周血中VDR mRNA表达水平。结果T2DM+OP组与单纯T2DM组相比,血浆中25(OH)D水平降低[(8.76±3.21)～(12.46±4.35) ng/mL,t=32.423,P=0.000],VDR mRNA表达水平降低[(0.35±0.12)～(1.07±0.23),t=15.365,P=0.001],而TG水平升高[(4.1±1.26)～(2.98±0.56) mmol/L,t=11.765,P=0.000];Pearson相关分析结果显示,血浆中VDR mRNA表达与25(OH)D水平呈正相关(相关系数r=0.717,P0.05),与HbAlc、HOMA-IR、Fins、FPG、2hPG、TG呈负相关(相关系数r分别为-0.342、-0.353、-0.361、-0.546、-0.426、-0.342,P0.05)。结论外周血中VDR mRNA表达、25(OH)D水平降低及TG水平的升高可能共同参与了T2DM、骨质疏松的发生发展。